nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.36485/1561-6274-2021-25-1-96-119nefr-1936Research ArticleПРОГРАММА НЕПРЕРЫВНОГО ПОСЛЕДИПЛОМНОГО ОБРАЗОВАНИЯ ПО НЕФРОЛОГИИPROGRAM ON CONTINUOUS POSTGRADUATE EDUCATION ON NEPHROLOGYПринципы ведения гломерулярных болезней (часть 2): итоги согласительной конференции Kidney disease: improving global outcomes (KDIGO) по спорным вопросамManagement and treatment of glomerular diseases (part 2): Conclusions From A Kidney Disease: Improving Global Outcomes (KDIGO) controversies conferenceРовинБрэд Х.RovinBrad H.

Подразделение Нефрологии

Brad H. Rovin - Division of Nephrology.

rovin.1@osu.eduКастерДоун Дж.CasterDawn J.

Отделение медицины

Department of Medicine

КаттранДэниел К.CattranDaniel C.ГибсонКейша Л.GibsonKeisha L.

Чапел-Хилл, Северная Каролина

ХоганДжонатан Дж.HoganJonathan J.

Подразделение Нефрологии

Филадельфия, Пенсильвания

Division of Nephrology

МюллерМаркус Дж.MoellerMarcus J.

Подразделение нефрологии и клинической иммунологии

Division of Nephrology and Clinical Immunology

РокателлоДариоRoccatelloDario

Центр исследования иммунопатологии и редких заболеваний, отделение нефрологии и диализа (член Европейской ассоциации редких болезней почек)

ЧеунгМайклCheungMichaelВилерДэвид К.WheelerDavid C.ВинкелмайерВольфганг К.WinkelmayerWolfgang C.

Сельцманский институт здоровья почек, Секция Нефрологии, Отделение медицины

Хьюстон, Техас

 

ФлёгеЮргенFloegeJurgen

Юрген Флёге - Подразделение Нефрологии и клинической Иммунологии.

Пау-элсштрассе 30, 52057 Аахен

Jurgen Floege - Division of Nephrology and Clinical Immunology.

jfloege@ukaachen.deУниверситет штата Огайо, медицинский центр УэкснерСоединённые Штаты АмерикиThe Ohio State University, Wexner Medical CenterUnited StatesУниверситет Школа медицины ЛуисвиллаСоединённые Штаты АмерикиUniversity of Louisville School of MedicineUnited StatesГлавный научно-исследовательский институт г. Торонто, Университетская сеть здравоохраненияКанадаToronto General Research Institute, University Health NetworkCanadaНефрологический центр Чапел-Хилла Университета Северной КаролиныСоединённые Штаты АмерикиUniversity of North Carolina Kidney Center at Chapel HillUnited StatesУниверситет ПенсильванииСоединённые Штаты АмерикиUniversity of PennsylvaniaUnited StatesРейнско-Вестфальский технический университетГерманияRheinisch-Westfalische Technische Hochschule, University of AachenGermanyУниверситет ТуринаИталияUniversity of TurinItalyKDIGOБельгияKDIGOBelgiumУниверситетский колледжВеликобританияUniversity College LondonUnited KingdomМедицинский колледж БэйлорСоединённые Штаты АмерикиSelzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of MedicineUnited StatesРейнско-Вестфальский технический университет г. АахенаГерманияDivision of NephrologyGermany20212101202125196119Copyright © Ровин Б., Кастер Д., Каттран Д., Гибсон К., Хоган Д., Мюллер М., Рокателло Д., Чеунг М., Вилер Д., Винкелмайер В., Флёге Ю., 20212021Ровин Б., Кастер Д., Каттран Д., Гибсон К., Хоган Д., Мюллер М., Рокателло Д., Чеунг М., Вилер Д., Винкелмайер В., Флёге Ю.Rovin B., Caster D., Cattran D., Gibson K., Hogan J., Moeller M., Roccatello D., Cheung M., Wheeler D., Winkelmayer W., Floege J.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/1936

По инициативе KDIGO (Kidney Disease: Improving Global Outcomes) в ноябре 2017 года была организована конференция по спорным вопросам в отношении гломерулярных болезней. В фокусе конференции были клинические рекомендации KDIGO 2012 года и новый взгляд на номенклатуру, патогенез, диагностику и лечение гломерулярных болезней, сформировавшийся с момента публикации рекомендаций. В ходе конференции Рабочая группа рассмотрела данные в отношении патогенеза, биомаркеров и лечения с целью выявления областей, где мнения экспертов совпадают и где разнятся. Данный отчет суммирует результаты дискуссии по первичным подоцитопатиям, волчаночному нефриту, АНЦА-ассоциированному нефриту, комплемент-опосредованным поражениям почек и моноклональной гаммапатии ренального значения.

In November 2017, the Kidney Disease: Improving Global Outcomes (KDIGO) initiative brought a diverse panel of experts in glomerular diseases together to discuss the 2012 KDIGO glomerulonephritis guideline in the context of new developments and insights that had occurred over the years since its publication. During this KDIGO Controversies Conference on Glomerular Diseases, the group examined data on disease pathogenesis, biomarkers, and treatments to identify areas of consensus and areas of controversy. This report summarizes the discussions on primary podocytopathies, lupus nephritis, anti-neutrophil cytoplasmic antibody-associated nephritis, complement mediated kidney diseases, and monoclonal gammopathies of renal significance.

АНЦА-ассоциированный васкулитС3-гломерулопатияфокально-сегментальный громелуроскле-розKDIGOволчаночный нефритмембранопролиферативный гломерулонефритболезнь минимальных изменениймоноклональная гаммапатия ренального значенияanti-neutrophil cytoplasmic antibody-associated vasculitisC3-glomerulopathyfocal and segmental glomerulosclerosisKDIGOlupus nephritismembranoproliferative glomerulonephritisminimal change diseasemonoclonal gam-mopathies of renal significanceСпонсором конференции является KDIGO, и частично финансирование осуществлено за счет образовательных грантов следующих компаний: Achillion, Aurinia Pharmaceuticals, Calliditas Therapeutics, ChemoCen-tryx, Chugai, Expedition Therapeutics, Gilead, Goldfinch Bio, Kyowa Kirin, Mallinckrodt Pharmaceuticals, Novartis, Omeros, Sanofi Genzyme, and Vifor Fresenius Medical Care Renal PharmaThe conference was sponsored by KDIGO and supported in part by unrestricted educational grants from Achil-lion, Aurinia Pharmaceuticals, Calliditas Therapeutics, ChemoCen-tryx, Chugai, Expedition Therapeutics, Gilead, Goldfinch Bio, Kyowa Kirin, Mallinckrodt Pharmaceuticals, Novartis, Omeros, Sanofi Genzyme, and Vifor Fresenius Medical Care Renal PharmaReferencesKidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2012;2:139-274. doi: 10.1038/kisup.2012.12Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2012;2:139-274. doi: 10.1038/kisup.2012.12Corwin HL, Schwartz MM, Lewis EJ. The importance of sample size in the interpretation of the renal biopsy. Am J Nephrol 1988; 8:85-89. doi: 10.1159/000167563Corwin HL, Schwartz MM, Lewis EJ. The importance of sample size in the interpretation of the renal biopsy. Am J Nephrol 1988; 8:85-89. doi: 10.1159/000167563Vivarelli M, Massella L, Ruggiero B et al. Minimal change disease. Clin J Am Soc Nephrol 2017;12:332-345. doi: 10.2215/CJN.05000516Vivarelli M, Massella L, Ruggiero B et al. Minimal change disease. Clin J Am Soc Nephrol 2017;12:332-345. doi: 10.2215/CJN.05000516Rosenberg AZ, Kopp JB. Focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2017;12:502-517. doi: 10.2215/CJN.05960616Rosenberg AZ, Kopp JB. Focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2017;12:502-517. doi: 10.2215/CJN.05960616De Vriese AS, Sethi S, Nath KA et al. Differentiating primary, genetic, and secondary FSGS in adults: a clinicopathologic approach. J Am Soc Nephrol 2018;29:759-774. doi: 10.1681/ASN.2017090958De Vriese AS, Sethi S, Nath KA et al. Differentiating primary, genetic, and secondary FSGS in adults: a clinicopathologic approach. J Am Soc Nephrol 2018;29:759-774. doi: 10.1681/ASN.2017090958Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 1974;2:556-560. doi: 10.1016/s0140-6736(74)91880-7Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 1974;2:556-560. doi: 10.1016/s0140-6736(74)91880-7Maas RJ, Deegens JK, Wetzels JF. Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future. Nephrol Dial Transplant 2014;29:2207-2216. doi: 10.1093/ndt/gfu355Maas RJ, Deegens JK, Wetzels JF. Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future. Nephrol Dial Transplant 2014;29:2207-2216. doi: 10.1093/ndt/gfu355Hayek SS, Sever S, Ko YA et al. Soluble urokinase receptor and chronic kidney disease. N Engl J Med 2015;373:1916-1925. doi: 10.1056/NEJMoa1506362Hayek SS, Sever S, Ko YA et al. Soluble urokinase receptor and chronic kidney disease. N Engl J Med 2015;373:1916-1925. doi: 10.1056/NEJMoa1506362Clement LC, Avila-Casado C, Mace C et al. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoidsensitive nephrotic syndrome. Nat Med 2011;17:117-122. doi: 10.1038/nm.2261Clement LC, Avila-Casado C, Mace C et al. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoidsensitive nephrotic syndrome. Nat Med 2011;17:117-122. doi: 10.1038/nm.2261McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010;5:2115-2121. doi: 10.2215/CJN.03800609McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010;5:2115-2121. doi: 10.2215/CJN.03800609Shin JI, Kronbichler A. Rituximab for patients with nephrotic syndrome. Lancet 2015;385:225-226. doi: 10.1016/S0140-6736(15)60050-2Shin JI, Kronbichler A. Rituximab for patients with nephrotic syndrome. Lancet 2015;385:225-226. doi: 10.1016/S0140-6736(15)60050-2Novelli R, Gagliardini E, Ruggiero B et al. Any value of podocyte B7-1 as a biomarker in human MCD and FSGS? Am J Physiol Renal Physiol 2016;310:F335-F341. doi: 10.1152/ajpre-nal.00510.2015Novelli R, Gagliardini E, Ruggiero B et al. Any value of podocyte B7-1 as a biomarker in human MCD and FSGS? Am J Physiol Renal Physiol 2016;310:F335-F341. doi: 10.1152/ajpre-nal.00510.2015Shankland SJ, Smeets B, Pippin JW et al. The emergence of the glomerular parietal epithelial cell. Nat Rev Nephrol 2014;10:158-173. doi: 10.1038/nrneph.2014.1Shankland SJ, Smeets B, Pippin JW et al. The emergence of the glomerular parietal epithelial cell. Nat Rev Nephrol 2014;10:158-173. doi: 10.1038/nrneph.2014.1D’Agati VD, Fogo AB, Bruijn JA et al. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 2004;43:368-382. doi: 10.1053/j.ajkd.2003.10.024D’Agati VD, Fogo AB, Bruijn JA et al. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 2004;43:368-382. doi: 10.1053/j.ajkd.2003.10.024D’Agati VD, Alster JM, Jennette JC et al. Association of histologic variants in FSGS clinical trial with presenting features and outcomes. Clin J Am Soc Nephrol 2013;8:399-406. doi: 10.2215/CJN.06100612D’Agati VD, Alster JM, Jennette JC et al. Association of histologic variants in FSGS clinical trial with presenting features and outcomes. Clin J Am Soc Nephrol 2013;8:399-406. doi: 10.2215/CJN.06100612Smeets B, Stucker F, Wetzels J et al. Detection of activated parietal epithelial cells on the glomerular tuft distinguishes early focal segmental glomerulosclerosis from minimal change disease. Am J Pathol 2014;184:3239-3248. doi: 10.1016/j.aj-path.2014.08.007Smeets B, Stucker F, Wetzels J et al. Detection of activated parietal epithelial cells on the glomerular tuft distinguishes early focal segmental glomerulosclerosis from minimal change disease. Am J Pathol 2014;184:3239-3248. doi: 10.1016/j.aj-path.2014.08.007Gbadegesin RA, Winn MP, Smoyer WE. Genetic testing in nephrotic syndrome - challenges and opportunities. Nat Rev Nephrol 2013;9:179-184. doi: 10.1038/nrneph.2012.286Gbadegesin RA, Winn MP, Smoyer WE. Genetic testing in nephrotic syndrome - challenges and opportunities. Nat Rev Nephrol 2013;9:179-184. doi: 10.1038/nrneph.2012.286Lovric S, Ashraf S, Tan W et al. Genetic testing in steroid-resistant nephrotic syndrome: when and how? Nephrol Dial Transplant 2016;31:1802-1813. doi: 10.1093/ndt/gfv355Lovric S, Ashraf S, Tan W et al. Genetic testing in steroid-resistant nephrotic syndrome: when and how? Nephrol Dial Transplant 2016;31:1802-1813. doi: 10.1093/ndt/gfv355Sadowski CE, Lovric S, Ashraf S et al. A single-gene cause in 29.5 % of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2015;26:1279-1289. doi: 10.1681/ASN.2014050489Sadowski CE, Lovric S, Ashraf S et al. A single-gene cause in 29.5 % of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2015;26:1279-1289. doi: 10.1681/ASN.2014050489Trautmann A, Schnaidt S, Lipska-Zietkiewicz BS et al. Long-term outcome of steroid-resistant nephrotic syndrome in children. J Am Soc Nephrol 2017;28:3055-3065. doi: 10.1681/ASN.2016101121Trautmann A, Schnaidt S, Lipska-Zietkiewicz BS et al. Long-term outcome of steroid-resistant nephrotic syndrome in children. J Am Soc Nephrol 2017;28:3055-3065. doi: 10.1681/ASN.2016101121Trautmann A, Bodria M, Ozaltin F et al. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. Clin J Am Soc Nephrol 2015;10:592-600. doi: 10.2215/CJN.06260614Trautmann A, Bodria M, Ozaltin F et al. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. Clin J Am Soc Nephrol 2015;10:592-600. doi: 10.2215/CJN.06260614Teeninga N, Kist-van Holthe JE, van Rijswijk N et al. Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome. J Am Soc Nephrol 2013;24:149-159. doi: 10.1681/ASN.2012070646Teeninga N, Kist-van Holthe JE, van Rijswijk N et al. Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome. J Am Soc Nephrol 2013;24:149-159. doi: 10.1681/ASN.2012070646Sinha A, Saha A, Kumar M et al. Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroidsensitive nephrotic syndrome. Kidney Int 2015;87:217-224. doi: 10.1038/ki.2014.240Sinha A, Saha A, Kumar M et al. Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroidsensitive nephrotic syndrome. Kidney Int 2015;87:217-224. doi: 10.1038/ki.2014.240Yoshikawa N, Nakanishi K, Sako M et al. A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney Int 2015;87:225-232. doi: 10.1038/ki.2014.260Yoshikawa N, Nakanishi K, Sako M et al. A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney Int 2015;87:225-232. doi: 10.1038/ki.2014.260Yadav M, Sinha A, Hari P, Bagga A. Efficacy of low-dose daily versus alternate day prednisone in children with frequently relapsing nephrotic syndrome (FRNS): open-label randomized controlled trial (RCT). Abstract FP-S25-09. Pediatr Nephrol 2016;31:1752Yadav M, Sinha A, Hari P, Bagga A. Efficacy of low-dose daily versus alternate day prednisone in children with frequently relapsing nephrotic syndrome (FRNS): open-label randomized controlled trial (RCT). Abstract FP-S25-09. Pediatr Nephrol 2016;31:1752Iijima K, Sako M, Nozu K et al. Rituximab for childhoodonset, complicated, frequently relapsing nephrotic syndrome or steroiddependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2014;384:1273-1281. doi: 10.1016/S0140-6736(14)60541-9Iijima K, Sako M, Nozu K et al. Rituximab for childhoodonset, complicated, frequently relapsing nephrotic syndrome or steroiddependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2014;384:1273-1281. doi: 10.1016/S0140-6736(14)60541-9Kim AH, Chung JJ, Akilesh S et al. B cell-derived IL-4 acts on podocytes to induce proteinuria and foot process effacement. JCI Insight 2017;2.pii:81836. doi: 10.1172/jci.insight.81836Kim AH, Chung JJ, Akilesh S et al. B cell-derived IL-4 acts on podocytes to induce proteinuria and foot process effacement. JCI Insight 2017;2.pii:81836. doi: 10.1172/jci.insight.81836Gellermann J, Weber L, Pape L et al. Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol 2013;24:1689-1697. doi: 10.1681/ASN.2012121200Gellermann J, Weber L, Pape L et al. Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol 2013;24:1689-1697. doi: 10.1681/ASN.2012121200Masse V, Al Jijakli A, Genet P et al. Screening and management of hepatitis B virus before the first rituximab infusion: We must do better! Blood 2014;124:2754. Available at: http://www.bloodjournal.org/content/124/21/2754. Accessed March 15, 2018. doi: 0.1182/blood.V124.21.2754.2754Masse V, Al Jijakli A, Genet P et al. Screening and management of hepatitis B virus before the first rituximab infusion: We must do better! Blood 2014;124:2754. Available at: http://www.bloodjournal.org/content/124/21/2754. Accessed March 15, 2018. doi: 0.1182/blood.V124.21.2754.2754Sethi S, Haas M, Markowitz GS et al. Mayo Clinic/Renal Pathology Society Consensus report on pathologic classification, diagnosis, and reporting of GN. J Am Soc Nephrol 2016;27:1278-1287. doi: 10.1681/ASN.2015060612Sethi S, Haas M, Markowitz GS et al. Mayo Clinic/Renal Pathology Society Consensus report on pathologic classification, diagnosis, and reporting of GN. J Am Soc Nephrol 2016;27:1278-1287. doi: 10.1681/ASN.2015060612Fervenza FC, Sethi S, Glassock RJ. Idiopathic membra-noproliferative glomerulonephritis: does it exist? Nephrol Dial Transplant 2012;27:4288-4294. doi: 10.1093/ndt/gfs288Fervenza FC, Sethi S, Glassock RJ. Idiopathic membra-noproliferative glomerulonephritis: does it exist? Nephrol Dial Transplant 2012;27:4288-4294. doi: 10.1093/ndt/gfs288Nasr SH, Galgano SJ, Markowitz GS et al. Immunofluorescence on pronase-digested paraffin sections: a valuable salvage technique for renal biopsies. Kidney Int 2006;70:2148-2151. doi: 10.1038/sj.ki.5001990Nasr SH, Galgano SJ, Markowitz GS et al. Immunofluorescence on pronase-digested paraffin sections: a valuable salvage technique for renal biopsies. Kidney Int 2006;70:2148-2151. doi: 10.1038/sj.ki.5001990Larsen CP, Ambuzs JM, Bonsib SM et al. Membranous-like glomerulopathy with masked IgG kappa deposits. Kidney Int 2014;86:154-161. doi: 10.1038/ki.2013.548Larsen CP, Ambuzs JM, Bonsib SM et al. Membranous-like glomerulopathy with masked IgG kappa deposits. Kidney Int 2014;86:154-161. doi: 10.1038/ki.2013.548Messias NC, Walker PD, Larsen CP. Paraffin immunofluorescence in the renal pathology laboratory: more than a salvage technique. Mod Pathol 2015;28:854-860. doi: 10.1038/mod-pathol.2015.1Messias NC, Walker PD, Larsen CP. Paraffin immunofluorescence in the renal pathology laboratory: more than a salvage technique. Mod Pathol 2015;28:854-860. doi: 10.1038/mod-pathol.2015.1Larsen CP, Messias NC, Walker PD et al. Membranoprolif-erative glomerulonephritis with masked monotypic immunoglobulin deposits. Kidney Int 2015;88:867-873. doi: 10.1038/ki.2015.195Larsen CP, Messias NC, Walker PD et al. Membranoprolif-erative glomerulonephritis with masked monotypic immunoglobulin deposits. Kidney Int 2015;88:867-873. doi: 10.1038/ki.2015.195Sethi S, Nasr SH, De Vriese AS et al. C4d as a diagnostic tool in proliferative GN. J Am Soc Nephrol 2015;26:2852-2859. doi: 10.1681/ASN.2014040406Sethi S, Nasr SH, De Vriese AS et al. C4d as a diagnostic tool in proliferative GN. J Am Soc Nephrol 2015;26:2852-2859. doi: 10.1681/ASN.2014040406Andeen NK, Yang HY, Dai DF et al. DnaJ homolog subfamily B member 9 is a putative autoantigen in fibrillary GN. J Am Soc Nephrol 2018;29:231-239. doi: 10.1681/ASN.2017050566Andeen NK, Yang HY, Dai DF et al. DnaJ homolog subfamily B member 9 is a putative autoantigen in fibrillary GN. J Am Soc Nephrol 2018;29:231-239. doi: 10.1681/ASN.2017050566Dasari S, Alexander MP, Vrana JA et al. DnaJ heat shock protein family B member 9 is a novel biomarker for fibrillary GN. J Am Soc Nephrol 2018;29:51-56. doi: 10.1681/ASN.2017030306Dasari S, Alexander MP, Vrana JA et al. DnaJ heat shock protein family B member 9 is a novel biomarker for fibrillary GN. J Am Soc Nephrol 2018;29:51-56. doi: 10.1681/ASN.2017030306Pickering MC, D’Agati VD, Nester CM et al. C3 glomerulopathy: consensus report. Kidney Int 2013;84:1079-1089. doi: 10.1038/ki.2013.377Pickering MC, D’Agati VD, Nester CM et al. C3 glomerulopathy: consensus report. Kidney Int 2013;84:1079-1089. doi: 10.1038/ki.2013.377Goodship TH, Cook HT, Fakhouri F et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2017;91:539-551. doi: 10.1016/j.kint.2016.10.005Goodship TH, Cook HT, Fakhouri F et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2017;91:539-551. doi: 10.1016/j.kint.2016.10.005Servais A, Noel LH, Roumenina LT et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012;82:454-464. doi: 10.1038/ki.2012.63Servais A, Noel LH, Roumenina LT et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012;82:454-464. doi: 10.1038/ki.2012.63Iatropoulos P, Daina E, Curreri M et al. Cluster analysis identifies distinct pathogenetic patterns in C3 glomerulopathies/ immune complexmediated membranoproliferative GN. J Am Soc Nephrol 2018;29:283-294. doi: 10.1681/ASN.2017030258Iatropoulos P, Daina E, Curreri M et al. Cluster analysis identifies distinct pathogenetic patterns in C3 glomerulopathies/ immune complexmediated membranoproliferative GN. J Am Soc Nephrol 2018;29:283-294. doi: 10.1681/ASN.2017030258Zand L, Kattah A, Fervenza FC et al. C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am J Kidney Dis 2013;62:506-514. doi: 10.1053/j.ajkd.2013.02.370Zand L, Kattah A, Fervenza FC et al. C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am J Kidney Dis 2013;62:506-514. doi: 10.1053/j.ajkd.2013.02.370Avasare RS, Canetta PA, Bomback AS et al. Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: a case series. Clin J Am Soc Nephrol 2018;13:406-413. doi: 10.2215/CJN.09080817Avasare RS, Canetta PA, Bomback AS et al. Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: a case series. Clin J Am Soc Nephrol 2018;13:406-413. doi: 10.2215/CJN.09080817Rabasco C, Cavero T, Roman E et al. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 2015;88:1153-1160. doi: 10.1038/ki.2015.227Rabasco C, Cavero T, Roman E et al. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 2015;88:1153-1160. doi: 10.1038/ki.2015.227Caliskan Y, Torun ES, Tiryaki TO et al. Immunosuppressive treatment in C3 glomerulopathy: is it really effective? Am J Nephrol 2017;46:96-107. doi: 10.1159/000479012Caliskan Y, Torun ES, Tiryaki TO et al. Immunosuppressive treatment in C3 glomerulopathy: is it really effective? Am J Nephrol 2017;46:96-107. doi: 10.1159/000479012Chauvet S, Fremeaux-Bacchi V, Petitprez F et al. Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. Blood 2017;129:1437-1447. doi: 10.1182/blood-2016-08-737163Chauvet S, Fremeaux-Bacchi V, Petitprez F et al. Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. Blood 2017;129:1437-1447. doi: 10.1182/blood-2016-08-737163Vignon M, Cohen C, Faguer S et al. The clinicopathologic characteristics of kidney diseases related to monotypic IgA deposits. Kidney Int 2017;91:720-728. doi: 10.1016/j.kint.2016.10.026Vignon M, Cohen C, Faguer S et al. The clinicopathologic characteristics of kidney diseases related to monotypic IgA deposits. Kidney Int 2017;91:720-728. doi: 10.1016/j.kint.2016.10.026Bonaud A, Bender S, Touchard G et al. A mouse model recapitulating human monoclonal heavy chain deposition disease evidences the relevance of proteasome inhibitor therapy. Blood 2015;126:757-765. doi: 10.1182/blood-2015-03-630277Bonaud A, Bender S, Touchard G et al. A mouse model recapitulating human monoclonal heavy chain deposition disease evidences the relevance of proteasome inhibitor therapy. Blood 2015;126:757-765. doi: 10.1182/blood-2015-03-630277Bridoux F, Javaugue V, Bender S et al. Unravelling the im-munopathological mechanisms of heavy chain deposition disease with implications for clinical management. Kidney Int 2017;91:423-434. doi: 10.1016/j.kint.2016.09.004Bridoux F, Javaugue V, Bender S et al. Unravelling the im-munopathological mechanisms of heavy chain deposition disease with implications for clinical management. Kidney Int 2017;91:423-434. doi: 10.1016/j.kint.2016.09.004Cohen C, Royer B, Javaugue V et al. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int 2015;88:1135-1143. doi: 10.1038/ki.2015.201Cohen C, Royer B, Javaugue V et al. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int 2015;88:1135-1143. doi: 10.1038/ki.2015.201Bridoux F, Leung N, Hutchison CA et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int 2015;87:698-711. doi: 10.1038/ki.2014.408Bridoux F, Leung N, Hutchison CA et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int 2015;87:698-711. doi: 10.1038/ki.2014.408Gumber R, Cohen JB, Palmer MB et al. A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits. Kidney Int 2018;94:199-205. doi: 10.1016/j.kint.2018.02.020Gumber R, Cohen JB, Palmer MB et al. A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits. Kidney Int 2018;94:199-205. doi: 10.1016/j.kint.2018.02.020Bhutani G, Nasr SH, Said SM et al. Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. Mayo Clin Proc 2015; 90: 587-596. doi: 10.1016/j.mayocp.2015.01.024Bhutani G, Nasr SH, Said SM et al. Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. Mayo Clin Proc 2015; 90: 587-596. doi: 10.1016/j.mayocp.2015.01.024Kumar S, Paiva B, Anderson KC et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:e328-e346. doi: 10.1016/S1470-2045(16)30206-6Kumar S, Paiva B, Anderson KC et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:e328-e346. doi: 10.1016/S1470-2045(16)30206-6Comenzo RL, Reece D, Palladini G et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 2012;26:2317-2325. doi: 10.1038/leu.2012.100Comenzo RL, Reece D, Palladini G et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 2012;26:2317-2325. doi: 10.1038/leu.2012.100Palladini G, Dispenzieri A, Gertz MA et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541-4549. doi: 10.1200/JCO.2011.37.7614Palladini G, Dispenzieri A, Gertz MA et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541-4549. doi: 10.1200/JCO.2011.37.7614Dimopoulos MA, Roussou M, Gavriatopoulou M et al. Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit. Blood Cancer J 2017;7:e571. doi: 10.1038/bcj.2017.49Dimopoulos MA, Roussou M, Gavriatopoulou M et al. Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit. Blood Cancer J 2017;7:e571. doi: 10.1038/bcj.2017.49Palladini G, Hegenbart U, Milani P et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 2014;124:2325-2332. doi: 10.1182/blood-2014-04-570010Palladini G, Hegenbart U, Milani P et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 2014;124:2325-2332. doi: 10.1182/blood-2014-04-570010Vignon M, Javaugue V, Alexander MP et al. Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients. Leukemia 2017;31:123-129. doi: 10.1038/leu.2016.195Vignon M, Javaugue V, Alexander MP et al. Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients. Leukemia 2017;31:123-129. doi: 10.1038/leu.2016.195Fermand JP, Bridoux F, Kyle RA et al. How I treat monoclonal gammopathy of renal significance (MGRS). Blood 2013;122:3583-3590. doi: 10.1182/blood-2013-05-495929Fermand JP, Bridoux F, Kyle RA et al. How I treat monoclonal gammopathy of renal significance (MGRS). Blood 2013;122:3583-3590. doi: 10.1182/blood-2013-05-495929Sawinski D, Lim MA, Cohen JB et al. Patient and kidney allograft survival in recipients with end-stage renal disease from amyloidosis. Transplantation 2018;102:300-309. doi: 10.1097/TP.0000000000001930Sawinski D, Lim MA, Cohen JB et al. Patient and kidney allograft survival in recipients with end-stage renal disease from amyloidosis. Transplantation 2018;102:300-309. doi: 10.1097/TP.0000000000001930Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 clinical practice guideline on the prevention, diagnosis, evaluation, and treatment of hepatitis c in chronic kidney disease. Kidney Int Suppl 2018;8:91-165. doi: 10.1016/j.kisu.2018.06.001Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 clinical practice guideline on the prevention, diagnosis, evaluation, and treatment of hepatitis c in chronic kidney disease. Kidney Int Suppl 2018;8:91-165. doi: 10.1016/j.kisu.2018.06.001Levine JW, Gota C, Fessler BJ et al. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol 2005;32:1164-1167Levine JW, Gota C, Fessler BJ et al. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol 2005;32:1164-1167Landau DA, Saadoun D, Halfon P et al. Relapse of hepatitis C virus associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum 2008;58:604-611. doi: 10.1002/art.23305Landau DA, Saadoun D, Halfon P et al. Relapse of hepatitis C virus associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum 2008;58:604-611. doi: 10.1002/art.23305Ghosn M, Palmer MB, Najem CE et al. New-onset hepatitis C virus associated glomerulonephritis following sustained virologic response with direct-acting antiviral therapy. Clin Nephrol 2017;87:261-266. doi: 10.5414/CN109019Ghosn M, Palmer MB, Najem CE et al. New-onset hepatitis C virus associated glomerulonephritis following sustained virologic response with direct-acting antiviral therapy. Clin Nephrol 2017;87:261-266. doi: 10.5414/CN109019Artemova M, Abdurakhmanov D, Ignatova T et al. Persistent hepatitis C virus-associated cryoglobulinemic vasculitis following virus eradication after direct-acting antiviral therapy. Hepatology 2017;65:1770-1771. doi: 10.1002/hep.28981Artemova M, Abdurakhmanov D, Ignatova T et al. Persistent hepatitis C virus-associated cryoglobulinemic vasculitis following virus eradication after direct-acting antiviral therapy. Hepatology 2017;65:1770-1771. doi: 10.1002/hep.28981Hogan J, Restivo M, Canetta PA et al. Rituximab treatment for Fibrillary glomerulonephritis. Nephrol Dial Transplant 2014;29:1925-1931. doi: 10.1093/ndt/gfu189Hogan J, Restivo M, Canetta PA et al. Rituximab treatment for Fibrillary glomerulonephritis. Nephrol Dial Transplant 2014;29:1925-1931. doi: 10.1093/ndt/gfu189Javaugue V, Karras A, Glowacki F et al. Long-term kidney disease outcomes in fibrillary glomerulonephritis: a case series of 27 patients. Am J Kidney Dis 2013;62:679-690. doi: 10.1053/j.ajkd.2013.03.031Javaugue V, Karras A, Glowacki F et al. Long-term kidney disease outcomes in fibrillary glomerulonephritis: a case series of 27 patients. Am J Kidney Dis 2013;62:679-690. doi: 10.1053/j.ajkd.2013.03.031Kalbermatter SA, Marone C, Casartelli D et al. Outcome of Fibrillary glomerulonephritis. Swiss Med Wkly 2012;142:w13578. doi: 10.4414/smw.2012.13578Kalbermatter SA, Marone C, Casartelli D et al. Outcome of Fibrillary glomerulonephritis. Swiss Med Wkly 2012;142:w13578. doi: 10.4414/smw.2012.13578Nasr SH, Valeri AM, Cornell LD et al. Fibrillary glomerulonephritis: a report of 66 cases from a single institution. Clin J Am Soc Nephrol 2011;6:775-784. doi: 10.2215/CJN.08300910Nasr SH, Valeri AM, Cornell LD et al. Fibrillary glomerulonephritis: a report of 66 cases from a single institution. Clin J Am Soc Nephrol 2011;6:775-784. doi: 10.2215/CJN.08300910Rosenstock JL, Markowitz GS, Valeri AM et al. Fibrillary and immunotactoid glomerulonephritis: distinct entities with different clinical and pathologic features. Kidney Int 2003;63:1450-1461. doi: 10.1046/j.1523-1755.2003.00853.xRosenstock JL, Markowitz GS, Valeri AM et al. Fibrillary and immunotactoid glomerulonephritis: distinct entities with different clinical and pathologic features. Kidney Int 2003;63:1450-1461. doi: 10.1046/j.1523-1755.2003.00853.xWeening JJ, D’Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004;65:521-530. doi: 0.1097/01.asn.0000108969.21691.5dWeening JJ, D’Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004;65:521-530. doi: 0.1097/01.asn.0000108969.21691.5dYu F, Wu LH, Tan Y et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney Int 2010;77:820-829. doi: 10.1038/ki.2010.13Yu F, Wu LH, Tan Y et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney Int 2010;77:820-829. doi: 10.1038/ki.2010.13Wu LH, Yu F, Tan Y et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int 2013; 83: 715-723. doi: 10.1038/ki.2012.409Wu LH, Yu F, Tan Y et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int 2013; 83: 715-723. doi: 10.1038/ki.2012.409Hu W, Chen Y, Wang S et al. Clinical-morphological features and outcomes of lupus podocytopathy. Clin J Am Soc Nephrol 2016;11:585-592. doi: 10.2215/CJN.06720615Hu W, Chen Y, Wang S et al. Clinical-morphological features and outcomes of lupus podocytopathy. Clin J Am Soc Nephrol 2016;11:585-592. doi: 10.2215/CJN.06720615Yu F, Haas M, Glassock R et al. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol 2017;13:483-495. doi: 10.1038/nrneph.2017.85Yu F, Haas M, Glassock R et al. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol 2017;13:483-495. doi: 10.1038/nrneph.2017.85Yu F, Tan Y, Liu G et al. Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int 2009;76:307-317. doi: 10.1038/ki.2009.136Yu F, Tan Y, Liu G et al. Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int 2009;76:307-317. doi: 10.1038/ki.2009.136Hsieh C, Chang A, Brandt D et al. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res 2011;63:865-874. doi: 10.1002/acr.20441Hsieh C, Chang A, Brandt D et al. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res 2011;63:865-874. doi: 10.1002/acr.20441Mejia-Vilet JM, Cordova-Sanchez BM, Uribe-Uribe NO et al. Prognostic significance of renal vascular pathology in lupus nephritis. Lupus 2017;26:1042-1050. doi: 10.1177/0961203317692419Mejia-Vilet JM, Cordova-Sanchez BM, Uribe-Uribe NO et al. Prognostic significance of renal vascular pathology in lupus nephritis. Lupus 2017;26:1042-1050. doi: 10.1177/0961203317692419Haring CM, Rietveld A, van den Brand JA et al. Segmental and global subclasses of class IV lupus nephritis have similar renal outcomes. J Am Soc Nephrol 2012;23:149-154. doi: 10.1681/ASN.2011060558Haring CM, Rietveld A, van den Brand JA et al. Segmental and global subclasses of class IV lupus nephritis have similar renal outcomes. J Am Soc Nephrol 2012;23:149-154. doi: 10.1681/ASN.2011060558Schwartz MM, Korbet SM, Lewis EJ et al. The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol Dial Transplant 2008;23:1298-1306. doi: 10.1093/ndt/gfm775Schwartz MM, Korbet SM, Lewis EJ et al. The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol Dial Transplant 2008;23:1298-1306. doi: 10.1093/ndt/gfm775Bajema IM, Wilhelmus S, Alpers CE et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 2018;93:789-796. doi: 10.1016/j.kint.2017.11.023Bajema IM, Wilhelmus S, Alpers CE et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 2018;93:789-796. doi: 10.1016/j.kint.2017.11.023Petri M, Orbai AM, Alarcon GS et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-2686. doi: 10.1002/art.34473Petri M, Orbai AM, Alarcon GS et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-2686. doi: 10.1002/art.34473Rijnink EC, Teng YKO, Kraaij T et al. Validation of the Systemic Lupus International Collaborating Clinics classification criteria in a cohort of patients with full house glomerular deposits. Kidney Int 2018;93:214-220. doi: 10.1016/j.kint.2017.07.017Rijnink EC, Teng YKO, Kraaij T et al. Validation of the Systemic Lupus International Collaborating Clinics classification criteria in a cohort of patients with full house glomerular deposits. Kidney Int 2018;93:214-220. doi: 10.1016/j.kint.2017.07.017Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011;365:2110-2121. doi: 0.1056/NEJMra1100359Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011;365:2110-2121. doi: 0.1056/NEJMra1100359Munroe ME, James JA. Genetics of lupus nephritis: clinical implications. Semin Nephrol 2015;35:396-409. doi: 10.1016/j.semnephrol.2015.08.002Munroe ME, James JA. Genetics of lupus nephritis: clinical implications. Semin Nephrol 2015;35:396-409. doi: 10.1016/j.semnephrol.2015.08.002Caster DJ, Korte EA, Nanda SK et al. ABIN1 dysfunction as a genetic basis for lupus nephritis. J Am Soc Nephrol 2013;24:1743-1754. doi: 10.1681/ASN.2013020148Caster DJ, Korte EA, Nanda SK et al. ABIN1 dysfunction as a genetic basis for lupus nephritis. J Am Soc Nephrol 2013;24:1743-1754. doi: 10.1681/ASN.2013020148Bomback AS, Gharavi AG. Lupus nephritis: ancestry, genetic risk and health disparities. Nat Rev Nephrol 2013;9:699-700. doi: 10.1038/nrneph.2013.210Bomback AS, Gharavi AG. Lupus nephritis: ancestry, genetic risk and health disparities. Nat Rev Nephrol 2013;9:699-700. doi: 10.1038/nrneph.2013.210Ceccarelli F, Perricone C, Borgiani P et al. Genetic factors in systemic lupus erythematosus: contribution to disease phenotype. J Immunol Res 2015:745647. doi: 10.1155/2015/745647Ceccarelli F, Perricone C, Borgiani P et al. Genetic factors in systemic lupus erythematosus: contribution to disease phenotype. J Immunol Res 2015:745647. doi: 10.1155/2015/745647Freedman BI, Langefeld CD, Andringa KK et al. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol 2014;66:390-396. doi: 10.1002/art.38220Freedman BI, Langefeld CD, Andringa KK et al. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol 2014;66:390-396. doi: 10.1002/art.38220Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1-150. doi: 10.1038/kisup.2012.76Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1-150. doi: 10.1038/kisup.2012.76Condon MB, Ashby D, Pepper RJ et al. Prospective observational singlecentre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013;72:1280-1286. doi: 10.1136/annrheumdis-2012-202844Condon MB, Ashby D, Pepper RJ et al. Prospective observational singlecentre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013;72:1280-1286. doi: 10.1136/annrheumdis-2012-202844Malvar A, Pirruccio P, Alberton V et al. Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant 2017;32:1338-1344. doi: 10.1093/ndt/gfv296Malvar A, Pirruccio P, Alberton V et al. Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant 2017;32:1338-1344. doi: 10.1093/ndt/gfv296Parikh SV, Alvarado A, Malvar A et al. The kidney biopsy in lupus nephritis: past, present, and future. Semin Nephrol 2015;35:465-477. doi: 10.1016/j.semnephrol.2015.08.008.Parikh SV, Alvarado A, Malvar A et al. The kidney biopsy in lupus nephritis: past, present, and future. Semin Nephrol 2015;35:465-477. doi: 10.1016/j.semnephrol.2015.08.008.Alvarado AS, Malvar A, Lococo B et al. The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients. Lupus 2014;23:840-847. doi: 10.1177/0961203313518625Alvarado AS, Malvar A, Lococo B et al. The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients. Lupus 2014;23:840-847. doi: 10.1177/0961203313518625Zickert A, Sundelin B, Svenungsson E et al. Role of early repeated renal biopsies in lupus nephritis. Lupus Sci Med 2014;1:e000018. doi: 10.1136/lupus-2014-000018Zickert A, Sundelin B, Svenungsson E et al. Role of early repeated renal biopsies in lupus nephritis. Lupus Sci Med 2014;1:e000018. doi: 10.1136/lupus-2014-000018Dall’Era M, Cisternas MG, Smilek DE et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol 2015;67:1305-1313. doi: 10.1002/art.39026Dall’Era M, Cisternas MG, Smilek DE et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol 2015;67:1305-1313. doi: 10.1002/art.39026Tamirou F, D’Cruz D, Sangle S et al. Long-term followup of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis 2016;75:526-531. doi: 10.1136/annrheum-dis-2014-206897Tamirou F, D’Cruz D, Sangle S et al. Long-term followup of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis 2016;75:526-531. doi: 10.1136/annrheum-dis-2014-206897Ugolini-Lopes MR, Seguro LPC, Castro MXF et al. Early proteinuria response: a valid real-life situation predictor of longterm lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis? Lupus Sci Med 2017;4:e000213. doi: 10.1136/lupus-2017-000213Ugolini-Lopes MR, Seguro LPC, Castro MXF et al. Early proteinuria response: a valid real-life situation predictor of longterm lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis? Lupus Sci Med 2017;4:e000213. doi: 10.1136/lupus-2017-000213Birmingham DJ, Shidham G, Perna A et al. Spot PC ratio estimates of 24-hour proteinuria are more unreliable in lupus nephritis than in other forms of chronic glomerular disease. Ann Rheum Dis 2014;73:475-476. doi: 10.1136/annrheumdis-2013-203790Birmingham DJ, Shidham G, Perna A et al. Spot PC ratio estimates of 24-hour proteinuria are more unreliable in lupus nephritis than in other forms of chronic glomerular disease. Ann Rheum Dis 2014;73:475-476. doi: 10.1136/annrheumdis-2013-203790Yang XW, Tan Y, Yu F et al. Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis. Nephrol Dial Transplant 2012;27:3552-3559. doi: 10.1093/ndt/gfs179Yang XW, Tan Y, Yu F et al. Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis. Nephrol Dial Transplant 2012;27:3552-3559. doi: 10.1093/ndt/gfs179Orbai AM, Truedsson L, Sturfelt G et al. Anti-C1q antibodies in systemic lupus erythematosus. Lupus 2015;24:42-49. doi: 10.1177/0961203314547791Orbai AM, Truedsson L, Sturfelt G et al. Anti-C1q antibodies in systemic lupus erythematosus. Lupus 2015;24:42-49. doi: 10.1177/0961203314547791Soliman S, Mohan C. Lupus nephritis biomarkers. Clin Immunol 2017;185:10-20. doi: 10.1016/j.clim.2016.08.001Soliman S, Mohan C. Lupus nephritis biomarkers. Clin Immunol 2017;185:10-20. doi: 10.1016/j.clim.2016.08.001Phatak S, Chaurasia S, Mishra SK et al. Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): potential biomarkers of active lupus nephritis. Clin Exp Immunol 2017;187:376-382. doi: 10.1111/cei.12894Phatak S, Chaurasia S, Mishra SK et al. Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): potential biomarkers of active lupus nephritis. Clin Exp Immunol 2017;187:376-382. doi: 10.1111/cei.12894Xuejing Z, Jiazhen T, Jun L et al. Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases. J Biomed Biotechnol 2012;2012:359647. doi: 10.1155/2012/359647Xuejing Z, Jiazhen T, Jun L et al. Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases. J Biomed Biotechnol 2012;2012:359647. doi: 10.1155/2012/359647Reyes-Thomas J, Blanco I, Putterman C. Urinary biomarkers in lupus nephritis. Clin Rev Allergy Immunol 2011;40:138-150. doi: 10.1007/s12016-010-8197-zReyes-Thomas J, Blanco I, Putterman C. Urinary biomarkers in lupus nephritis. Clin Rev Allergy Immunol 2011;40:138-150. doi: 10.1007/s12016-010-8197-zParikh SV, Malvar A, Song H et al. Molecular imaging of the kidney in lupus nephritis to characterize response to treatment. Transl Res 2017;182:1-13. doi: 10.1016/j.trsl.2016.10.010Parikh SV, Malvar A, Song H et al. Molecular imaging of the kidney in lupus nephritis to characterize response to treatment. Transl Res 2017;182:1-13. doi: 10.1016/j.trsl.2016.10.010Parikh SV, Malvar A, Song H et al. Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders. Lupus Sci Med 2015;2:e000112. doi: 10.1136/lupus-2015-000112Parikh SV, Malvar A, Song H et al. Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders. Lupus Sci Med 2015;2:e000112. doi: 10.1136/lupus-2015-000112Banchereau R, Hong S, Cantarel B et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 2016;165:551-565. doi: 10.1016/j.cell.2016.03.008Banchereau R, Hong S, Cantarel B et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 2016;165:551-565. doi: 10.1016/j.cell.2016.03.008Pons-Estel GJ, Alarcon GS, Burgos PI et al. Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance: data from a Latin American cohort. Lupus 2013;22:899-907. doi: 10.1177/0961203313496339Pons-Estel GJ, Alarcon GS, Burgos PI et al. Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance: data from a Latin American cohort. Lupus 2013;22:899-907. doi: 10.1177/0961203313496339Ugarte-Gil MF, Wojdyla D, Pastor-Asurza CA et al. Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic Latin American cohort. Lupus 2018;27:536-544. doi: 10.1177/0961203317728810Ugarte-Gil MF, Wojdyla D, Pastor-Asurza CA et al. Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic Latin American cohort. Lupus 2018;27:536-544. doi: 10.1177/0961203317728810Fessler BJ, Alarcon GS, McGwin G Jr et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005;52:1473-1480. doi: 10.1002/art.21039Fessler BJ, Alarcon GS, McGwin G Jr et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005;52:1473-1480. doi: 10.1002/art.21039Galindo-Izquierdo M, Rodriguez-Almaraz E, Pego-Reigo-sa JM et al. Characterization of patients with lupus nephritis included in a large cohort from the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER). Medicine 2016;95:e2891. doi: 10.1097/MD.0000000000002891Galindo-Izquierdo M, Rodriguez-Almaraz E, Pego-Reigo-sa JM et al. Characterization of patients with lupus nephritis included in a large cohort from the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER). Medicine 2016;95:e2891. doi: 10.1097/MD.0000000000002891Joo YB, Won S, Choi CB et al. Lupus nephritis is associated with more corticosteroid-associated organ damage but less corticosteroid nonassociated organ damage. Lupus 2017;26:598-605. doi: 10.1177/0961203316671813Joo YB, Won S, Choi CB et al. Lupus nephritis is associated with more corticosteroid-associated organ damage but less corticosteroid nonassociated organ damage. Lupus 2017;26:598-605. doi: 10.1177/0961203316671813Sciascia S, Mompean E, Radin M et al. Rate of adverse effects of medium- to high-dose glucocorticoid therapy in systemic lupus erythematosus: a systematic review of randomized control trials. Clin Drug Investig 2017;37:519-524. doi: 10.1007/s40261-017-0518-zSciascia S, Mompean E, Radin M et al. Rate of adverse effects of medium- to high-dose glucocorticoid therapy in systemic lupus erythematosus: a systematic review of randomized control trials. Clin Drug Investig 2017;37:519-524. doi: 10.1007/s40261-017-0518-zRoccatello D, Sciascia S, Baldovino S et al. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment: clinical response compared to literature and immunological re-assessment. Autoimmun Rev 2015;14:1123-1130. doi: 10.1016/j.autrev.2015.07.01Roccatello D, Sciascia S, Baldovino S et al. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment: clinical response compared to literature and immunological re-assessment. Autoimmun Rev 2015;14:1123-1130. doi: 10.1016/j.autrev.2015.07.01Ruiz-Irastorza G, Ugarte A, Saint-Pastou Terrier C et al. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: an observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun Rev 2017;16:826-832. doi: 10.1016/j.autrev.2017.05.017Ruiz-Irastorza G, Ugarte A, Saint-Pastou Terrier C et al. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: an observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun Rev 2017;16:826-832. doi: 10.1016/j.autrev.2017.05.017Liu Z, Zhang H, Liu Z et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 2015;162:18-26. doi: 10.7326/M14-1030Liu Z, Zhang H, Liu Z et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 2015;162:18-26. doi: 10.7326/M14-1030Zhang H, Liu Z, Zhou M et al. Multitarget therapy for maintenance treatment of lupus nephritis. J Am Soc Nephrol 2017;28:3671-3678. doi: 10.1681/ASN.2017030263Zhang H, Liu Z, Zhou M et al. Multitarget therapy for maintenance treatment of lupus nephritis. J Am Soc Nephrol 2017;28:3671-3678. doi: 10.1681/ASN.2017030263Dooley MA, Jayne D, Ginzler EM et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886-1895. doi: 10.1056/NEJMoa1014460Dooley MA, Jayne D, Ginzler EM et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886-1895. doi: 10.1056/NEJMoa1014460Houssiau FA, D’Cruz D, Sangle S et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010;69:2083-2089. doi: 10.1136/ard.2010.131995Houssiau FA, D’Cruz D, Sangle S et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010;69:2083-2089. doi: 10.1136/ard.2010.131995Lenz O, Waheed AA, Baig A et al. Lupus nephritis: maintenance therapy for lupus nephritis: Do we now have a plan? Clin J Am Soc Nephrol 2013;8:162-171. doi: 10.2215/CJN.03640412Lenz O, Waheed AA, Baig A et al. Lupus nephritis: maintenance therapy for lupus nephritis: Do we now have a plan? Clin J Am Soc Nephrol 2013;8:162-171. doi: 10.2215/CJN.03640412Moroni G, Gallelli B, Quaglini S et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant 2006;21:1541-1548. doi: 10.1093/ndt/gfk073Moroni G, Gallelli B, Quaglini S et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant 2006;21:1541-1548. doi: 10.1093/ndt/gfk073Grootscholten C, Berden JH. Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible? Nephrol Dial Transplant 2006;21:1465-1469. doi: 10.1093/ndt/gfl208Grootscholten C, Berden JH. Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible? Nephrol Dial Transplant 2006;21:1465-1469. doi: 10.1093/ndt/gfl208Ioannidis JP, Boki KA, Katsorida ME et al. Remission, relapse, and reremission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000;57:258-264. doi: 10.1046/j.1523-1755.2000.00832.xIoannidis JP, Boki KA, Katsorida ME et al. Remission, relapse, and reremission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000;57:258-264. doi: 10.1046/j.1523-1755.2000.00832.xMok CC, Ying KY, Tang S et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004; 50:2559-2568. doi: 10.1002/art.20364Mok CC, Ying KY, Tang S et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004; 50:2559-2568. doi: 10.1002/art.20364Rovin BH, Furie R, Latinis K et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215-1226. doi: 10.1002/art.34359Rovin BH, Furie R, Latinis K et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215-1226. doi: 10.1002/art.34359Duxbury B, Combescure C, Chizzolini C. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus 2013;22:1489-1503. doi: 10.1177/0961203313509295Duxbury B, Combescure C, Chizzolini C. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus 2013;22:1489-1503. doi: 10.1177/0961203313509295Shamliyan TA, Dospinescu P. Additional improvements in clinical response from adjuvant biologic response modifiers in adults with moderate to severe systemic lupus erythematosus despite immunosuppressive agents: a systematic review and meta-analysis. Clin Ther 2017;39:1479-1506. doi: 10.1016/j.clinthera.2017.05.359Shamliyan TA, Dospinescu P. Additional improvements in clinical response from adjuvant biologic response modifiers in adults with moderate to severe systemic lupus erythematosus despite immunosuppressive agents: a systematic review and meta-analysis. Clin Ther 2017;39:1479-1506. doi: 10.1016/j.clinthera.2017.05.359Moroni G, Raffiotta F, Trezzi B et al. Rituximab vs myco-phenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Rheumatology 2014;53:1570-1577. doi: 10.1093/rheumatology/ket46Moroni G, Raffiotta F, Trezzi B et al. Rituximab vs myco-phenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Rheumatology 2014;53:1570-1577. doi: 10.1093/rheumatology/ket46Mok CC, Yap DY, Navarra SV et al. Overview of lupus nephritis management guidelines and perspective from Asia. Int J Rheum Dis 2013;16:625-636. doi: 10.1111/1756-185X.12212Mok CC, Yap DY, Navarra SV et al. Overview of lupus nephritis management guidelines and perspective from Asia. Int J Rheum Dis 2013;16:625-636. doi: 10.1111/1756-185X.12212Chavarot N, Verhelst D, Pardon A et al. Rituximab alone as induction therapy for membranous lupus nephritis: a multicenter retrospective study. Medicine 2017;96:e7429. doi: 10.1097/MD.0000000000007429Chavarot N, Verhelst D, Pardon A et al. Rituximab alone as induction therapy for membranous lupus nephritis: a multicenter retrospective study. Medicine 2017;96:e7429. doi: 10.1097/MD.0000000000007429Song D, Wu LH, Wang FM et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther 2013;15:R12. doi: 10.1186/ar414Song D, Wu LH, Wang FM et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther 2013;15:R12. doi: 10.1186/ar414Pattanashetti N, Anakutti H, Ramachandran R et al. Effect of thrombotic microangiopathy on clinical outcomes in Indian patients with lupus nephritis. Kidney Int Rep 2017;2:844-849. doi: 10.1016/j.ekir.2017.04.008Pattanashetti N, Anakutti H, Ramachandran R et al. Effect of thrombotic microangiopathy on clinical outcomes in Indian patients with lupus nephritis. Kidney Int Rep 2017;2:844-849. doi: 10.1016/j.ekir.2017.04.008Chen MH, Chen MH, Chen WS et al. Thrombotic microangiopathy in systemic lupus erythematosus: a cohort study in North Taiwan. Rheumatology 2011;50:768-775. doi: 10.1093/rheumatology/keq31Chen MH, Chen MH, Chen WS et al. Thrombotic microangiopathy in systemic lupus erythematosus: a cohort study in North Taiwan. Rheumatology 2011;50:768-775. doi: 10.1093/rheumatology/keq31Kronbichler A, Brezina B, Quintana LF et al. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review. Autoimmun Rev 2016;15:38-49. doi: 10.1016/j.autrev.2015.08.010Kronbichler A, Brezina B, Quintana LF et al. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review. Autoimmun Rev 2016;15:38-49. doi: 10.1016/j.autrev.2015.08.010Sciascia S, Radin M, Yazdany J et al. Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatol Int 2017;37:1249-1255. doi: 10.1007/s00296-017-3686-5Sciascia S, Radin M, Yazdany J et al. Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatol Int 2017;37:1249-1255. doi: 10.1007/s00296-017-3686-5de Holanda MI, Porto LC, Wagner T et al. Use of ecu-lizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3: a case report and systematic review. Clin Rheumatol 2017;36:2859-2867. doi: 10.1007/s10067-017-3823-2de Holanda MI, Porto LC, Wagner T et al. Use of ecu-lizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3: a case report and systematic review. Clin Rheumatol 2017;36:2859-2867. doi: 10.1007/s10067-017-3823-2Legendre CM, Licht C, Muus P et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;368:2169-2181. doi: 10.1056/NEJMoa1208981Legendre CM, Licht C, Muus P et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;368:2169-2181. doi: 10.1056/NEJMoa1208981Licht C, Greenbaum LA, Muus P et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 2015;87:1061-1073. doi: 10.1038/ki.2014.423Licht C, Greenbaum LA, Muus P et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 2015;87:1061-1073. doi: 10.1038/ki.2014.423Erkan D, Aguiar CL, Andrade D et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014;13:685-696. doi: 10.1016/j.autrev.2014.01.053Erkan D, Aguiar CL, Andrade D et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014;13:685-696. doi: 10.1016/j.autrev.2014.01.053Bienaime F, Legendre C, Terzi F et al. Antiphospholipid syndrome and kidney disease. Kidney Int 2017;91:34-44. doi: 10.1016/j.kint.2016.06.026Bienaime F, Legendre C, Terzi F et al. Antiphospholipid syndrome and kidney disease. Kidney Int 2017;91:34-44. doi: 10.1016/j.kint.2016.06.026Canaud G, Bienaime F, Tabarin F et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med 2014;371:303-312. doi: 10.1056/NEJMoa1312890Canaud G, Bienaime F, Tabarin F et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med 2014;371:303-312. doi: 10.1056/NEJMoa1312890Webster P, Wardle A, Bramham K et al. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. Lupus 2014;23:1192-1196. doi: 10.1177/0961203314540353Webster P, Wardle A, Bramham K et al. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. Lupus 2014;23:1192-1196. doi: 10.1177/0961203314540353O’Shaughnessy MM, Liu S, Montez-Rath ME et al. Kidney transplantation outcomes across GN subtypes in the United States. J Am Soc Nephrol 2017;28:632-644. doi: 10.1681/ASN.2016020126O’Shaughnessy MM, Liu S, Montez-Rath ME et al. Kidney transplantation outcomes across GN subtypes in the United States. J Am Soc Nephrol 2017;28:632-644. doi: 10.1681/ASN.2016020126Yu TM, Chen YH, Lan JL et al. Renal outcome and evolution of disease activity in Chinese lupus patients after renal transplantation. Lupus 2008;17:687-694. doi: 10.1177/0961203308089439Yu TM, Chen YH, Lan JL et al. Renal outcome and evolution of disease activity in Chinese lupus patients after renal transplantation. Lupus 2008;17:687-694. doi: 10.1177/0961203308089439Yu TM, Wen MC, Li CY et al. Impact of recurrent lupus nephritis on lupus kidney transplantation: a 20-year single center experience. Clin Rheumatol 2012;31:705-710. doi: 10.1007/s10067-011-1931-yYu TM, Wen MC, Li CY et al. Impact of recurrent lupus nephritis on lupus kidney transplantation: a 20-year single center experience. Clin Rheumatol 2012;31:705-710. doi: 10.1007/s10067-011-1931-yNaranjo-Escobar J, Manzi E, Posada JG et al. Kidney transplantation for end-stage renal disease in lupus nephritis, a very safe procedure: a single Latin American transplant center experience. Lupus 2017;26:1157-1165. doi: 10.1177/0961203317696591Naranjo-Escobar J, Manzi E, Posada JG et al. Kidney transplantation for end-stage renal disease in lupus nephritis, a very safe procedure: a single Latin American transplant center experience. Lupus 2017;26:1157-1165. doi: 10.1177/0961203317696591Contreras G, Mattiazzi A, Guerra G et al. Recurrence of lupus nephritis after kidney transplantation. J Am Soc Nephrol 2010; 21:1200-1207. doi: 10.1681/ASN.2009101093Contreras G, Mattiazzi A, Guerra G et al. Recurrence of lupus nephritis after kidney transplantation. J Am Soc Nephrol 2010; 21:1200-1207. doi: 10.1681/ASN.2009101093Briganti EM, Russ GR, McNeil JJ et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002;347:103-109. doi: 10.1056/NEJMoa013036Briganti EM, Russ GR, McNeil JJ et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002;347:103-109. doi: 10.1056/NEJMoa013036Mina R, von Scheven E, Ardoin SP et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res 2012;64:375-383. doi: 10.1002/acr.21558Mina R, von Scheven E, Ardoin SP et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res 2012;64:375-383. doi: 10.1002/acr.21558Hugle B, Silverman ED, Tyrrell PN et al. Presentation and outcome of paediatric membranous non-proliferative lupus nephritis. Pediatr Nephrol 2015;30:113-121. doi: 10.1007/s00467-014-2908-2Hugle B, Silverman ED, Tyrrell PN et al. Presentation and outcome of paediatric membranous non-proliferative lupus nephritis. Pediatr Nephrol 2015;30:113-121. doi: 10.1007/s00467-014-2908-2Pereira M, Muscal E, Eldin K et al. Clinical presentation and outcomes of childhood-onset membranous lupus nephritis. Pediatr Nephrol 2017;32:2283-2291. doi: 10.1007/s00467-017-3743-zPereira M, Muscal E, Eldin K et al. Clinical presentation and outcomes of childhood-onset membranous lupus nephritis. Pediatr Nephrol 2017;32:2283-2291. doi: 10.1007/s00467-017-3743-zGroot N, de Graeff N, Marks SD et al. European evidencebased recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis 2017;76:1965-1973. doi: 10.1136/annrheumdis-2017-211898Groot N, de Graeff N, Marks SD et al. European evidencebased recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis 2017;76:1965-1973. doi: 10.1136/annrheumdis-2017-211898Jennette JC, Nachman PH. ANCA glomerulonephritis and vasculitis. Clin J Am Soc Nephrol 2017;12:1680-1691. doi: 10.2215/CJN.02500317Jennette JC, Nachman PH. ANCA glomerulonephritis and vasculitis. Clin J Am Soc Nephrol 2017;12:1680-1691. doi: 10.2215/CJN.02500317Roth AJ, Ooi JD, Hess JJ et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest 2013;123:1773-1783. doi: 10.1172/JCI65292Roth AJ, Ooi JD, Hess JJ et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest 2013;123:1773-1783. doi: 10.1172/JCI65292Lionaki S, Blyth ER, Hogan SL et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase3 in disease recognition and prognosis. Arthritis Rheum 2012;64:3452-3462. doi: 10.1002/art.34562Lionaki S, Blyth ER, Hogan SL et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase3 in disease recognition and prognosis. Arthritis Rheum 2012;64:3452-3462. doi: 10.1002/art.34562Walsh M, Flossmann O, Berden A et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012;64:542-548. doi: 10.1002/art.33361Walsh M, Flossmann O, Berden A et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012;64:542-548. doi: 10.1002/art.33361Lyons PA, Rayner TF, Trivedi S et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012;367:214-223. doi: 10.1056/NEJMoa1108735Lyons PA, Rayner TF, Trivedi S et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012;367:214-223. doi: 10.1056/NEJMoa1108735Schreiber A, Xiao H, Jennette JC et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 2009;20:289-298. doi: 10.1681/ASN.2008050497Schreiber A, Xiao H, Jennette JC et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 2009;20:289-298. doi: 10.1681/ASN.2008050497Caster DJ, Powell DW, Miralda I et al. Re-examining neutrophil participation in GN. J Am Soc Nephrol 2017;28:2275-2289. doi: 10.1681/ASN.2016121271Caster DJ, Powell DW, Miralda I et al. Re-examining neutrophil participation in GN. J Am Soc Nephrol 2017;28:2275-2289. doi: 10.1681/ASN.2016121271Diaz-Crespo F, Villacorta J, Acevedo M et al. The predictive value of kidney biopsy in renal vasculitis: a multicenter cohort study. Hum Pathol 2016;52:119-127. doi: 10.1016/j.hum-path.2016.01.015Diaz-Crespo F, Villacorta J, Acevedo M et al. The predictive value of kidney biopsy in renal vasculitis: a multicenter cohort study. Hum Pathol 2016;52:119-127. doi: 10.1016/j.hum-path.2016.01.015Tomasson G, Grayson PC, Mahr AD et al. Value of ANCA measurements during remission to predict a relapse of ANCA-asso-ciated vasculitis: a meta-analysis. Rheumatology 2012;51:100-109. doi: 10.1093/rheumatology/ker280Tomasson G, Grayson PC, Mahr AD et al. Value of ANCA measurements during remission to predict a relapse of ANCA-asso-ciated vasculitis: a meta-analysis. Rheumatology 2012;51:100-109. doi: 10.1093/rheumatology/ker280Mukhtyar C, Lee R, Brown D et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009;68:1827-1832. doi: 10.1136/ard.2008.101279Mukhtyar C, Lee R, Brown D et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009;68:1827-1832. doi: 10.1136/ard.2008.101279Exley AR, Bacon PA, Luqmani RA et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-380. doi: 10.1002/art.1780400222Exley AR, Bacon PA, Luqmani RA et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-380. doi: 10.1002/art.1780400222Monach PA, Warner RL, Tomasson G et al. Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. Ann Rheum Dis 2013;72:1342-1350. doi: 10.1136/annrheumdis-2012-201981Monach PA, Warner RL, Tomasson G et al. Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. Ann Rheum Dis 2013;72:1342-1350. doi: 10.1136/annrheumdis-2012-201981Ishizaki J, Takemori A, Suemori K et al. Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Res Ther 2017;19:218. doi: 10.1186/s13075-017-1429-3Ishizaki J, Takemori A, Suemori K et al. Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Res Ther 2017;19:218. doi: 10.1186/s13075-017-1429-3O’Reilly VP, Wong L, Kennedy C et al. Urinary soluble CD163 in active renal vasculitis. J Am Soc Nephrol 2016;27:2906-2916. doi: 10.1681/ASN.2015050511O’Reilly VP, Wong L, Kennedy C et al. Urinary soluble CD163 in active renal vasculitis. J Am Soc Nephrol 2016;27:2906-2916. doi: 10.1681/ASN.2015050511Jayne DRW, Bruchfeld AN, Harper L et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 2017;28:2756-2767. doi: 10.1681/ASN.2016111179Jayne DRW, Bruchfeld AN, Harper L et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 2017;28:2756-2767. doi: 10.1681/ASN.2016111179Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-232. doi: 10.1056/NEJMoa0909905Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-232. doi: 10.1056/NEJMoa0909905Specks U, Merkel PA, Seo P et al. Efficacy of remissioninduction regimens for ANCA-associated vasculitis. N Engl J Med 2013;369:417-427. doi: 10.1056/NEJMoa1213277Specks U, Merkel PA, Seo P et al. Efficacy of remissioninduction regimens for ANCA-associated vasculitis. N Engl J Med 2013;369:417-427. doi: 10.1056/NEJMoa1213277Geetha D, Specks U, Stone JH et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol 2015;26:976-985. doi: 10.1681/ASN.2014010046Geetha D, Specks U, Stone JH et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol 2015;26:976-985. doi: 10.1681/ASN.2014010046Unizony S, Villarreal M, Miloslavsky EM et al. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis 2016;75:1166-1169. doi: 10.1136/annrheumdis-2015-208073Unizony S, Villarreal M, Miloslavsky EM et al. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis 2016;75:1166-1169. doi: 10.1136/annrheumdis-2015-208073Miloslavsky EM, Lu N, Unizony S et al. Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive and ANCA-negative patientswith granulomatosis with polyangiitis (Wegener’s): distinct patient subsets. Arthritis Rheumatol 2016;68:2945-2952. doi: 10.1002/art.39812Miloslavsky EM, Lu N, Unizony S et al. Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive and ANCA-negative patientswith granulomatosis with polyangiitis (Wegener’s): distinct patient subsets. Arthritis Rheumatol 2016;68:2945-2952. doi: 10.1002/art.39812Jones RB, Tervaert JW, Hauser T et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-220. doi: 10.1056/NEJMoa0909169Jones RB, Tervaert JW, Hauser T et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-220. doi: 10.1056/NEJMoa0909169Jones RB, Furuta S, Tervaert JW et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis 2015;74:1178-1182. doi: 10.1136/annrheumdis-2014-206404Jones RB, Furuta S, Tervaert JW et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis 2015;74:1178-1182. doi: 10.1136/annrheumdis-2014-206404Karras A, Pagnoux C, Haubitz M et al. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis 2017;76:1662-1668. doi: 10.1136/annrheumdis-2017-211123Karras A, Pagnoux C, Haubitz M et al. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis 2017;76:1662-1668. doi: 10.1136/annrheumdis-2017-211123Roccatello D, Sciascia S, Rossi D et al. The "4 plus 2" rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: a 10 years observation study. Oncotarget 2017;8:52072-52077. doi: 10.18632/oncotarget.18120Roccatello D, Sciascia S, Rossi D et al. The "4 plus 2" rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: a 10 years observation study. Oncotarget 2017;8:52072-52077. doi: 10.18632/oncotarget.18120Jones RB, Ferraro AJ, Chaudhry AN et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum 2009;60:2156-2168. doi: 10.1002/art.24637Jones RB, Ferraro AJ, Chaudhry AN et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum 2009;60:2156-2168. doi: 10.1002/art.24637Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010;5:1394-1400. doi: 10.2215/CJN.08821209Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010;5:1394-1400. doi: 10.2215/CJN.08821209Cartin-Ceba R, Golbin JM, Keogh KA et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): ten-year experience at a single center. Arthritis Rheum 2012;64:3770-3778. doi: 10.1002/art.34584Cartin-Ceba R, Golbin JM, Keogh KA et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): ten-year experience at a single center. Arthritis Rheum 2012;64:3770-3778. doi: 10.1002/art.34584Roubaud-Baudron C, Pagnoux C, Meaux-Ruault N et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 2012;39:125-130. doi: 10.3899/jrheum.110143Roubaud-Baudron C, Pagnoux C, Meaux-Ruault N et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 2012;39:125-130. doi: 10.3899/jrheum.110143Smith RM, Jones RB, Guerry MJ et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum 2012;64:3760-3769. doi: 10.1002/art.34583Smith RM, Jones RB, Guerry MJ et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum 2012;64:3760-3769. doi: 10.1002/art.34583Guillevin L, Pagnoux C, Karras A et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014;371: 1771-1780. doi: 10.1056/NEJMoa1404231Guillevin L, Pagnoux C, Karras A et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014;371: 1771-1780. doi: 10.1056/NEJMoa1404231Roccatello D. How I treat" autoimmune diseases: state of the art on the management of rare rheumatic diseases and ANCA-associated systemic idiopathic vasculitis. Autoimmun Rev 2017;16:995-998. doi: 10.1016/j.autrev.2017.07.015Roccatello D. How I treat" autoimmune diseases: state of the art on the management of rare rheumatic diseases and ANCA-associated systemic idiopathic vasculitis. Autoimmun Rev 2017;16:995-998. doi: 10.1016/j.autrev.2017.07.015Wilkinson NM, Page J, Uribe AG et al. Establishment of a pilot pediatric registry for chronic vasculitis is both essential and feasible: a Childhood Arthritis and Rheumatology Alliance (CARRA) survey. J Rheumatol 2007;34:224-226Wilkinson NM, Page J, Uribe AG et al. Establishment of a pilot pediatric registry for chronic vasculitis is both essential and feasible: a Childhood Arthritis and Rheumatology Alliance (CARRA) survey. J Rheumatol 2007;34:224-226Cabral DA, Canter DL, Muscal E et al. Comparing presenting clinical features in 48 children with microscopic polyangiitis to 183 children who have granulomatosis with polyangiitis (Wegener’s): an ARChiVe Cohort Study. Arthritis Rheumatol 2016;68:2514-2526. doi: 10.1002/art.39729Cabral DA, Canter DL, Muscal E et al. Comparing presenting clinical features in 48 children with microscopic polyangiitis to 183 children who have granulomatosis with polyangiitis (Wegener’s): an ARChiVe Cohort Study. Arthritis Rheumatol 2016;68:2514-2526. doi: 10.1002/art.39729Eleftheriou D, Melo M, Marks SD et al. Biologic therapy in primary systemic vasculitis of the young. Rheumatology 2009;48:978-986. doi: 10.1093/rheumatology/kep148Eleftheriou D, Melo M, Marks SD et al. Biologic therapy in primary systemic vasculitis of the young. Rheumatology 2009;48:978-986. doi: 10.1093/rheumatology/kep148James KE, Xiao R, Merkel PA et al. Clinical course and outcomes of childhood-onset granulomatosis with polyangiitis. Clin Exp Rheumatol 2017; 35 (suppl 103): 202-208James KE, Xiao R, Merkel PA et al. Clinical course and outcomes of childhood-onset granulomatosis with polyangiitis. Clin Exp Rheumatol 2017; 35 (suppl 103): 202-208

The authors declare that there are no conflicts of interest present.